These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17382784)

  • 21. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O
    J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: B.J. De Castro and K. C. Baker: Effect of flexible cystoscopy on serum prostate-specific antigen values (Urology 2009; 73:237-240).
    Romics I
    Urology; 2009 Jul; 74(1):234. PubMed ID: 19567303
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 27. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Malavaud B
    Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
    [No Abstract]   [Full Text] [Related]  

  • 28. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

  • 30. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
    Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
    Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords.
    Wilson RF; Henry TD
    J Am Coll Cardiol; 2005 Nov; 46(9):1649-50. PubMed ID: 16256863
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Descazeaud A; Peyromaure M; Salin A; Amsellem-Ouazana D; Flam T; Viellefond A; Debré B; Zerbib M
    Eur Urol; 2008 Feb; 53(2):355-61. PubMed ID: 17611015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
    Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
    Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
    Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
    Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
    BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 40. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.